DrugPatentWatch Database Preview
Drugs in Development Information for CRLX101
Email this page to a colleague
See Plans and PricingWhat is the drug development status for CRLX101?
CRLX101 is an investigational drug.
There have been 12 clinical trials for CRLX101.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Cerulean Pharma Inc., National Cancer Institute (NCI), and Abramson Cancer Center of the University of Pennsylvania.
There are four US patents protecting this investigational drug and twenty-three international patents.
Summary for CRLX101
| US Patents | 4 |
| International Patents | 23 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2011-06-01) |
| Vendors | 10 |
Recent Clinical Trials for CRLX101
| Title | Sponsor | Phase |
|---|---|---|
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | National Cancer Institute (NCI) | Phase 2 |
| Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | Cerulean Pharma Inc. | Phase 1 |
Clinical Trial Summary for CRLX101
Top disease conditions for CRLX101
Top clinical trial sponsors for CRLX101
US Patents for CRLX101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CRLX101 | Start Trial | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh (Pittsburgh, PA) | Start Trial |
| CRLX101 | Start Trial | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh (Pittsburgh, PA) | Start Trial |
| CRLX101 | Start Trial | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh--of the Commonwealth System of Higher Education (Pittsburgh, PA) | Start Trial |
| CRLX101 | Start Trial | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh - of The Commonwealth System of Higher Education (Pittsburgh, PA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CRLX101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CRLX101 | Austria | 418338 | 2017-08-29 | Start Trial |
| CRLX101 | Australia | 3123600 | 2017-08-29 | Start Trial |
| CRLX101 | Australia | 760543 | 2017-08-29 | Start Trial |
| CRLX101 | Australia | 777786 | 2017-08-29 | Start Trial |
| CRLX101 | Australia | 8476198 | 2017-07-02 | Start Trial |
| CRLX101 | Australia | 9205698 | 2017-08-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
